Dimerix Ltd
Dimerix Expands Kidney Pipeline With Phase 2-Ready Acquisition
Dimerix expands kidney pipeline with DMX-652 acquisition; Phase 2-ready AKI therapy targets US$3.5b market, upfront US$5m plus up to US$292m milestones.
Dimerix Engages Everest Medicines to Commercialise DMX-200 Kidney Disease Treatment across Asia
Dimerix inks exclusive DMX-200 FSGS deal with Everest in Asia; upfront $14.1m, potential milestones up to ~$466m and 15% royalties.
Dimerix Completes Adult Dosing for ACTION3 DMX-200 Trial
Dimerix completes adult dosing for ACTION3 DMX-200 in FSGS; 333 patients vs 286 target, boosting statistical power and de-risking regulatory submission.
Dimerix Reports Positive Data Supporting Action3 Study of DMX-200 to Treat Kidney Disease
Dimerix (ASX: DXB) has received final data analysis from the international PARASOL collaboration that reinforces support for proteinuria-based endpoints in its pivotal Phase 3 Action3 study on DMX-200 for the treatment of kidney disease. The multi-centre, randomised, double-blind, placebo-controlled study is testing the drug’s efficacy and safety in patients with focal segmental glomerulosclerosis (FSGS) who are […]